An Open-label Single Arm Multi-center Phase II Study to Assess Fruquintinib in High Risk Patients With Advanced Non-squamous Non-small Cell Lung Cancer
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Fruquintinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Hutchison MediPharma
- 17 Nov 2019 Planned End Date changed from 31 Oct 2019 to 6 Sep 2019.
- 17 Nov 2019 Planned primary completion date changed from 31 Oct 2019 to 6 Sep 2019.
- 17 Nov 2019 Status changed from recruiting to withdrawn prior to enrolment.